The company will buy 514,404 shares on the open market from Tuesday to Jan. 26, its second such tranche in less than a month.
Celltrion will decide at its March 2027 annual shareholders' meeting whether to cancel the shares, after weighing the move against a larger cash dividend.
The drugmaker said its market value has failed to keep pace with its earnings.
Its third-quarter operating profit surged 69.2 percent from a year earlier to a record 510 billion won on revenue of 1.5 trillion won, according to preliminary results released Oct. 12.
"We will consistently honor our mid- to long-term principle of returning one-third of consolidated net income to shareholders, and keep sharing the fruits of our growth with them," a Celltrion official said.
The company retired 9.11 million treasury shares worth about 1.78 trillion won in April, which it called its largest cancellation ever.
Celltrion shares fell 1.8 percent to 190,900 won in afternoon trading Monday, giving the company a market value of about 44.37 trillion won.
AJP Takeaways
- Celltrion said on Oct. 26, 2026 that it will buy back about 100 billion won of its shares between Oct. 27, 2026 and Jan. 26, 2027, bringing its 2026 buybacks to about 500 billion won.
- Celltrion posted a preliminary third-quarter 2026 operating profit of 510 billion won, up 69.2 percent from a year earlier, on revenue of 1.5 trillion won.
- Celltrion will decide at its March 2027 annual shareholders' meeting whether to cancel the repurchased shares or expand cash dividends instead.
Copyright ⓒ Aju Press All rights reserved.